breast cancer bone metastases
Oncology · 2008–2008
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ibandronic acid Treatment of bone metastases from breast cancer. Oral tablet formulation as an alternative to oral clodronate or intravenous bisphosphonates. | Mar 2008 | Not recommended | no section in document |
| ibandronic acid Bone metastases from breast cancer. The submission requested a Restricted Benefit listing for patients with bone metastases from breast cancer. | Nov 2008 | Recommended with restriction | no section in document |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| pamidronate disodiumPAMISOL pamidronate disodium 15mg/5mL injection vial | 2000 | 4 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.